CERo Therapeutics Reports Early Positive Data from CERTAIN-T Trial in High-Risk MDS/AML Patient — CERo Therapeutics Holdings, Inc.

Event summary

CERo Therapeutics will present interim Phase 1 data from the CERTAIN-T trial at the Tandem Meeting of ASTCT and CIBMTR on February 5, 2026.
The data highlight platelet transfusion independence in a high-risk MDS/AML patient after treatment with CER-1236, lasting over two months.
CER-1236 demonstrated a favorable safety profile with no dose-limiting toxicities or cytokine release syndrome (CRS) observed.
The trial has been amended to include transfusion-dependent myelodysplastic syndromes (TD-MDS), high-risk MDS (HR-MDS), and post-JAK-inhibitor myelofibrosis (MF).

The big picture

CERo Therapeutics' interim data from the CERTAIN-T trial underscores the potential of its novel phagocytic mechanism targeting TIM-4L, a differentiated approach compared to traditional CAR-T therapies. The positive safety and efficacy signals in high-risk MDS/AML patients highlight the company's progress in addressing unmet needs in myeloid diseases, an area with significant therapeutic challenges. The expansion of the trial to include additional patient populations suggests strategic flexibility in pursuing broader clinical applications.

What we're watching

Clinical Efficacy: Whether the observed platelet transfusion independence in high-risk MDS/AML patients can be replicated and sustained across larger patient cohorts.
Regulatory Pathway: The pace at which CERo Therapeutics advances CER-1236 through subsequent clinical phases, given the promising early data.
Market Differentiation: How CERo Therapeutics positions CER-1236 against existing CAR-T therapies and other cellular immunotherapies in the myeloid disease space.